Co-Diagnostics, Inc.
For the period ended Dec 31, 2025. Filed Mar 31, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 31, 2026
CODX$0.29-9.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Operations and Comprehensive Loss
| Years Ended December 31, | ||
|---|---|---|
| 2025 | 2024 | |
| Product revenue | $418,205 | $770,048 |
| Grant revenue | 204,284 | 3,145,112 |
| Total revenue | 622,489 | 3,915,160 |
| Cost of revenue | 222,377 | 999,124 |
| Gross profit | 400,112 | 2,916,036 |
| Operating expenses | ||
| Sales and marketing | 2,381,131 | 4,483,339 |
| General and administrative | 9,058,283 | 16,157,152 |
| Research and development | 19,137,242 | 20,979,589 |
| Depreciation and amortization | 1,106,808 | 1,377,266 |
| Impairment charges | 18,882,000 | - |
| Total operating expenses | 50,565,464 | 42,997,346 |
| Loss from operations | (50,165,352) | (40,081,310) |
| Other income, net | ||
| Interest income, net | 292,932 | 1,091,825 |
| Realized gain on investments | 683,365 | 870,745 |
| Gain (loss) on disposition of assets | (82,421) | 8,291 |
| Gain on remeasurement of acquisition contingencies | 805,863 | 714,876 |
| Loss on equity method investment in joint ventures | (46,301) | (186,067) |
| Total other income, net | 1,653,438 | 2,499,670 |
| Loss before income taxes | (48,511,914) | (37,581,640) |
| Income tax provision (benefit) | (1,615,978) | 57,368 |
| Net loss | $(46,895,936) | $(37,639,008) |
| Other comprehensive income (loss) | ||
| Change in net unrealized gains (losses) on marketable securities, net of tax | (418,443) | 271,743 |
| Total other comprehensive income (loss) | $(418,443) | $271,743 |
| Comprehensive loss | $(47,314,379) | $(37,367,265) |
| Loss per common share: | ||
| Basic and Diluted | $(35.25) | $(37.22) |
| Weighted average shares outstanding: | ||
| Basic and Diluted | 1,330,200 | 1,011,179 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.